New Ideas for Substance Use Condition Treatment: Could Psychedelics Help?

This is a past event

Event Description

New Ideas for Substance Use Condition Treatment: Could Psychedelics Help? provided an overview of psychedelic treatments, including ibogaine and psilocybin, for substance use conditions. During this panel discussion, an ibogaine researcher, a certified recovery coach with lived experience, and a drug law expert discussed existing research, potential benefits and risks, ongoing policy and legal reforms, and societal implications.

Panelists

  • Moderator: Stephanie Tabashneck, PsyD, JD, Senior Fellow of Law and Applied Neuroscience, Center for Law Brain and Behavior at Harvard Medical School and Petrie-Flom Center; Licensed Psychologist; and Director, Brain InCite Neurolaw Library
  • Deborah Mash, Professor of Neurology and Molecular and Cellular Pharmacology, Leonard M. Miller School of Medicine; Director, Brain Endowment Bank at the University of Miami; and Chief Executive Officer and Founder, DemeRx
  • Mark Guckel, CCAR Recovery Coach Professional, EntheoRecovery Solutions, LLC
  • Mason Marks, MD, JD, Visiting Professor of Law, Harvard Law School; Senior Fellow and Project Lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center; and Florida Bar Health Law Section Professor, Florida State University College of Law
VIDEO New Ideas for Substance Use Condition Treatment: Could Psychedelics Help?

 

This event is part of the Project on Psychedelics Law and Regulation (POPLAR) and the Project on Law and Applied Neuroscience, a collaboration between the Center for Law, Brain and Behavior at Massachusetts General Hospital and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School with support from the Oswald DeN. Cammann Fund at Harvard University.